Jeff Yass’s Elicio Therapeutics ELTX Stock Holding History

Jeff Yass’s Portfolio ELTX Stock Details ELTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$709K	Sell	181,400 -76,500	-30%	-$768K	﹤0.01%	9068
2026 Q1	$2.76M	Buy	+257,900	New	+$2.49M	﹤0.01%	5444

Other funds holding ELTX

KCM

Knoll Capital Management Miami, Florida $179M AUM 63.61% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Ikarian Capital Dallas, Texas $928M AUM 596.14% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM

AllianceBernstein Nashville, Tennessee $302B AUM 26.44% 1-Year Est. Return

Jeff Yass's ELTX Position: Q2 2026 in Review

Jeff Yass sold out of Elicio Therapeutics (ELTX) in Q2 2026, closing a stake of 70,804 shares — an estimated $711K sold.

Jeff Yass first reported a position in ELTX in Q2 2022 and held it in 7 quarters. The position peaked at $1.32M in Q3 2025. 48 funds tracked by Wall St. Rank hold ELTX as of Q2 2026.

Jeff Yass reported no remaining Elicio Therapeutics position as of Q2 2026 after selling out during the quarter.
Jeff Yass sold 70,804 Elicio Therapeutics shares in Q2 2026, an estimated $711K.
Jeff Yass first reported a position in Elicio Therapeutics in Q2 2022 and held it in 7 quarters.
Jeff Yass's Elicio Therapeutics position peaked at $1.32M in Q3 2025.
48 funds tracked by Wall St. Rank held Elicio Therapeutics as of Q2 2026.

Based on Susquehanna International Group's 13F filing for Q2 2026, filed 14 Aug 2026.